目的 探讨倍他司汀联合尼麦角林治疗脑梗死恢复期的临床疗效。方法 回顾性选取2022年6月—2024年6月芜湖市第五人民医院收治的脑梗死恢复期患者80例，按照随机数字法分为对照组和治疗组，每组40例。对照组口服尼麦角林胶囊，1粒/次，1次/d。在对照组基础上，治疗组口服盐酸倍他司汀片，2片/次，3次/d。两组治疗15 d。观察两组患者临床疗效，比较治疗前后两组患者Fugl-Meyer运动量表（FMA）和日常生活活动能力表（BI）评分及同型半胱氨酸（HCY）、神经生长因子（NGF）、白细胞介素-18(IL-18)和神经营养因子（NTF）水平。结果 治疗后，治疗组总有效率97.50%高于对照组的77.50%(P<0.05)。治疗后，两组患者FMA评分和BI评分比治疗前升高（P<0.05），且治疗后治疗组评分均高于对照组（P<0.05）。治疗后，两组患者HCY、IL-18水平比治疗前降低，而NGF、NTF水平升高（P<0.05），且治疗后，治疗组HCY、IL-18、NGF和NTF水平优于对照组（P<0.05）。结论 尼麦角林联合倍他司汀治疗脑梗死恢复期，能有效缓解患者症状，患者日常生活能力提升较高。

Objective To explore the clinical efficacy of betahistine combined with nicergoline in treatment of cerebral infarction in the recovery period. Methods A total of 80 patients in the convalescent stage of cerebral infarction admitted to the Fifth People’s Hospital of Wuhu from June 2022 to June 2024 were retrospectively selected and divided into control group（40 cases） and treatment group（40 cases） according to random number method. The control group took Nicergoline Capsules orally, 1 capsule/time, once a day.On the basis of the control group, the treatment group was given Betahistine Hydrochloride Tablets, 2 tablets/times, 3 times a day. Both groups were treated for 15 d. After treatment, the clinical evaluations were evaluated, the scores of FMA and BI, and the levels of HCY,NGF, NTF, and IL-18 in two groups before and after treatment were compared. Results After treatment, the total effective rate in the treatment group（97.50%） was significantly higher than that in the control group（77.50%, P＜0.05）. After treatment, the FMA scores and BI scores in two groups were significantly higher than those before treatment（P＜0.05）, and the scores in the treatment group were significantly higher than those in the control group（P＜0.05）. After treatment, the levels of HCY and IL-18 in two groups were significantly lower than those before treatment, while the levels of NGF and NTF were significantly higher（P＜0.05）. After treatment,the levels of HCY, IL-18, NGF, and NTF in the treatment group were significantly better than those in the control group（P＜0.05）.Conclusion The combination therapy of nicergoline and betahistine can effectively alleviate patients’ symptoms, improve their daily living ability.

R971